Hassan Elsayed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hassan Elsayed has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ahmed A. Yousif
Department of Gastroenterology and Infectious Diseases, Ahmed Maher Teaching Hospital, Cairo 11562, Egypt
1 shared publication- Ahmed Hassan Ibrahim Faraag
School of Biotechnology, Badr University in Cairo (BUC), Cairo 11829, Egypt
1 shared publication Ahmed Salah Seif
Department of Hepatogastroenterology and Infectious Diseases, Shebin Elkom Teaching Hospital, Cairo 32511, Egypt
1 shared publicationEnaya Ghaleb
School of Pharmacy, Newgiza University (NGU), Newgiza, Giza 12577, Egypt
1 shared publicationMohamed El‑Shiekh
Chest Department, Mataria Teaching Hospital, Cairo 11753, Egypt
1 shared publicationMohammad Shaaban Mahfouz
Department of Gastroenterology and Infectious Diseases, Ahmed Maher Teaching Hospital, Cairo 11562, Egypt
1 shared publication
Latest Publications
- Open Access
- 9 October 2024
- Published by Spandidos Publications in World Academy of Sciences Journal
- Vol. 6 (6) , 1-9
Association of OAS1 gene polymorphism with the severity of COVID‑19 infection
The ongoing coronavirus disease 2019 (COVID‑19) pandemic has underscored the critical need to investigate host genetic factors that may influence disease susceptibility and severity. Among these, the 2'‑5'‑oligoadenylate synthase 1 (OAS1) single nucleotide polymorphism (SNP) rs10774671 has been implicated in the antiviral response against coronaviruses and clinical outcomes. The aim of the present retrospective study was to investigate the association between the OAS1 gene polymorphism and the severity of COVID‑19. A total of 200 subjects were enrolled, including 75 healthy controls and 125 patients with COVID‑19. The OAS1 SNP rs10774671 was assessed using PCR‑RFLP analysis. The findings revealed an upward trend in the prevalence of the A allele among individuals, who developed a severe course of COVID‑19. Specifically, 17.8% of the patients with severe infection carried the GG genotype, 52.8% had the GA genotype and 30.4% carried the AA genotype (P=0.0001). Notably, the AA genotype was exclusively detected in patients with severe COVID‑19 infection (P<0.0001). Moreover, the frequency of the A allele was markedly higher than that of the G allele in patients with severe COVID‑19 infection (P=0.0001). Multivariate analysis revealed that individuals with the rs10774671 AA genotype had a 6.8‑fold greater likelihood of progressing to a more severe course of COVID‑19 (odds ratio, 6.86; 95% CI, 2.83‑16.63; P<0.0001). Thus, the OAS1 SNP rs10774671 holds promise as a potential genetic marker that could be valuable in predicting the progression and outcome of COVID‑19 infection.
- 9 October 2024
- Published by Spandidos Publications in World Academy of Sciences Journal
- Vol. 6 (6) , 1-9
Open AccessAssociation of OAS1 gene polymorphism with the severity of COVID‑19 infection
The ongoing coronavirus disease 2019 (COVID‑19) pandemic has underscored the critical need to investigate host genetic factors that may influence disease susceptibility and severity. Among these, the 2'‑5'‑oligoadenylate synthase 1 (OAS1) single nucleotide polymorphism (SNP) rs10774671 has been implicated in the antiviral response against coronaviruses and clinical outcomes. The aim of the present retrospective study was to investigate the association between the OAS1 gene polymorphism and the severity of COVID‑19. A total of 200 subjects were enrolled, including 75 healthy controls and 125 patients with COVID‑19. The OAS1 SNP rs10774671 was assessed using PCR‑RFLP analysis. The findings revealed an upward trend in the prevalence of the A allele among individuals, who developed a severe course of COVID‑19. Specifically, 17.8% of the patients with severe infection carried the GG genotype, 52.8% had the GA genotype and 30.4% carried the AA genotype (P=0.0001). Notably, the AA genotype was exclusively detected in patients with severe COVID‑19 infection (P<0.0001). Moreover, the frequency of the A allele was markedly higher than that of the G allele in patients with severe COVID‑19 infection (P=0.0001). Multivariate analysis revealed that individuals with the rs10774671 AA genotype had a 6.8‑fold greater likelihood of progressing to a more severe course of COVID‑19 (odds ratio, 6.86; 95% CI, 2.83‑16.63; P<0.0001). Thus, the OAS1 SNP rs10774671 holds promise as a potential genetic marker that could be valuable in predicting the progression and outcome of COVID‑19 infection.
- Open Access
- 28 April 2023
- Published by Elsevier in Saudi Journal of Biological Sciences
- Vol. 30 (6) , 103661
Harnessing immunoinformatics for developing a multiple-epitope peptide-based vaccination approach against SARS-CoV-2 spike protein
- 28 April 2023
- Published by Elsevier in Saudi Journal of Biological Sciences
- Vol. 30 (6) , 103661
Open AccessHarnessing immunoinformatics for developing a multiple-epitope peptide-based vaccination approach against SARS-CoV-2 spike protein